In our aggregated cohort, the tumor type distributions among BRAF, KRAS, and TP53 were as expected, with BRAF exhibiting a strong bias towards melanoma, KRAS exhibiting a strong bias towards NSCLC and TP53 exhibiting a pan tumor-type distribution (Supplementary Fig. 3). The gene discussed is KRAS; the disease is melanoma.